Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
On February 23, 2022, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced a mandatory conversion of its Multiple Voting Shares into Subordinate Voting Shares, effective March 14, 2022. Each Multiple Voting Share will convert to 100 Subordinate Voting Shares. This shift aims to simplify the company's capital structure and emphasizes MindMed's transition to a primarily U.S.-based company. CEO Robert Barrow highlighted that this move benefits both existing and new shareholders. MindMed is focused on developing psychedelic-inspired therapies for brain disorders.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has received FDA clearance for its Phase 2b trial of MM-120, a treatment for generalized anxiety disorder (GAD). This follows the lifting of a clinical hold after MindMed addressed FDA requests regarding participant monitoring. The trial will involve 200 participants and aims to assess anxiety symptom reduction post-administration of MM-120. CEO Robert Barrow highlighted this as a significant milestone, marking the first commercial use of LSD in clinical studies in over 40 years, aiming for improved treatment options for patients with anxiety.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the enrollment of the first subjects in its Session Monitoring System (SMS-01) study, aiming to evaluate sensory data collection during therapy sessions. The FDA provided positive feedback on the development strategy, supporting the study's design. The MSMS aims to enhance psychiatric care through innovative data analysis. MindMed focuses on psychedelic-inspired therapies for mental health and addiction, leveraging collaborations in its development pipeline.
On January 7, 2022, Mind Medicine (MindMed) (NASDAQ: MNMD) announced the resignation of Stephen Hurst from its Board of Directors. Hurst, who emphasized his commitment to psychedelic-inspired medicines for addiction and mental health, expressed confidence in the newly appointed directors and CEO Robert Barrow. The company is focused on developing innovative treatments based on psychedelic substances, including psilocybin and MDMA, and is approaching significant milestones in its clinical programs.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the successful completion of its Phase 1 clinical trial of 18-MC, a non-hallucinogenic treatment for opioid use disorder, in December 2021. Topline results are expected in early 2022, informing the design of a Phase 2a study focusing on safety and efficacy in opioid withdrawal. With promising safety and preclinical data, 18-MC aims to provide a safer alternative to ibogaine. The heightened opioid crisis, claiming over 75,000 lives annually, underscores the urgency for effective treatments.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will participate in the LifeSci Partners 11th Annual Corporate Access Event from January 5-7, 2022. CEO Robert Barrow is scheduled to take part in a panel titled "Psychedelics: More Than Just a Trip" on January 5 at 10:00 AM ET. The event will be held virtually, with a webcast available here. MindMed is pioneering psychedelic-inspired therapies aimed at addressing mental health issues and addiction, with a promising pipeline of treatments.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has announced transitions within its management team. Bradford Cross, Chief Technology Officer, is stepping down, while Don Gehlert, PhD, will shift from Chief Scientific Officer to Senior Scientific Advisor. CEO Robert Barrow expressed gratitude for their contributions and affirmed the company’s commitment to advancing its pipeline and digital therapeutics platform. The firm focuses on developing psychedelic-inspired therapies for mental health issues and continues to drive its innovative drug development pipeline.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that the FDA has placed a clinical hold on its IND submission for the Phase 2b trial of LSD aimed at treating generalized anxiety disorder (GAD). This decision halts the initiation of the trial pending further information, which is expected within 30 days. CEO Robert Barrow expressed a commitment to address FDA concerns promptly. GAD affects approximately 6% of U.S. adults over their lifetimes, highlighting the need for innovative treatments.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has launched a Phase 2a exploratory trial studying the effects of low-dose lysergic acid diethylamide (LSD) for treating adult attention deficit hyperactivity disorder (ADHD). Conducted in collaboration with University Hospital Basel and Maastricht University, the trial aims to evaluate the therapeutic potential of repeated low doses of LSD. The study will enroll 52 patients over six weeks, analyzing ADHD symptom changes. This trial is part of MindMed's broader development strategy for LSD therapies.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the appointment of Robert Barrow as CEO and Board member, effective immediately. Previously serving as interim CEO, Barrow brings extensive industry expertise, notably in psychedelic drug development. Carol Vallone has been appointed Chair of the Board, while Perry Dellelce transitions from Chairman. The company aims to advance its clinical development programs and expand its drug pipeline, focusing on psychedelic-inspired therapies for mental health.
FAQ
What is the current stock price of Mind Medicine (MNMD)?
What is the market cap of Mind Medicine (MNMD)?
